Sastasundar Ventures Limited — PPTs, 02-06-2025: Investor Presentation

1. Financial Highlights:

Revenue from operations declined 19.7% YoY to ₹1,088.5 Cr for FY25, with Q4 revenue down 6.8% YoY to ₹281.9 Cr. Gross profit dropped 41.9% YoY to ₹71.1 Cr, compressing gross margin to 6.5% from 9.0%. EBITDA widened to a negative ₹78.5 Cr versus -₹15.1 Cr last year. Net loss stood at ₹133.5 Cr against a profit of ₹5.9 Cr previously. The balance sheet shows strong liquidity with ₹656 Cr in liquid assets and a 34% reduction in working capital days to 23, indicating improved capital efficiency.

2. Strategic Initiatives & Growth Drivers:

Focus remains on expanding healthcare digital platforms across pharmacy, wellness, and diagnostics in both B2C and B2B (Retailer Shakti) channels. The company emphasizes working capital optimization and cost controls while leveraging technology to drive growth and customer engagement.

3. Business Developments:

No new acquisitions or partnerships announced. Efforts center on scaling existing supply chain operations, retail pharmacy, wellness, and diagnostics verticals. Financial services contribute a minor revenue stream, supporting diversification.

4. Market Position & Competitive Advantage:

The company stands out for capital efficiency, supported by a lean working capital cycle and strong liquidity. Its leadership in pharmacy supply chain and extensive network integration create a clear scale advantage and differentiation.

5. Investor Implications:

Despite wider losses and revenue pressure, improved working capital management and liquidity strengthen the base. Investors should monitor revenue trends and margin improvement as indicators of positive growth potential. Execution risks persist but management’s capital efficiency focus is encouraging.